Shoulder Innovations (NYSE:SI) Announces Earnings Results, Beats Expectations By $0.03 EPS

Shoulder Innovations (NYSE:SI) posted its quarterly earnings data on Wednesday. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.03, FiscalAI reports. Shoulder Innovations had a negative net margin of 85.29% and a negative return on equity of 37.68%. The company had revenue of $16.71 million during the quarter.

Here are the key takeaways from Shoulder Innovations’ conference call:

• First-quarter revenue beat expectations, with net revenue of $16.7 million up 65% year over year and 16% sequentially, while gross margin improved to 77.7%.
• The company raised full-year 2026 revenue guidance to $65 million-$68 million, up from $62 million-$65 million, reflecting confidence in new surgeon adoption, higher utilization, and product launches.
• Commercial momentum remained strong as total implant volume rose 51% year over year, with new customers entering the funnel faster and existing core surgeons increasing usage.
• The company advanced its product pipeline, including full commercial launch of the i135RFX humeral stem, limited user release of the N22 Glenosphere, and progress on its robotic platform with a 510(k) submission targeted for 2027.
• Operating expenses increased, with SG&A and R&D both higher year over year, but management said cash burn should decline meaningfully from Q2 onward and reiterated confidence in reaching cash flow breakeven over time.

Shoulder Innovations Stock Performance

SI stock opened at $13.56 on Thursday. Shoulder Innovations has a twelve month low of $10.92 and a twelve month high of $17.94. The firm has a market cap of $281.11 million and a price-to-earnings ratio of -0.06. The business’s fifty day simple moving average is $14.02 and its two-hundred day simple moving average is $13.98. The company has a quick ratio of 9.55, a current ratio of 11.07 and a debt-to-equity ratio of 0.11.

Insider Transactions at Shoulder Innovations

In related news, CFO Jeffrey S. Points purchased 2,000 shares of the business’s stock in a transaction dated Friday, March 13th. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $30,000.00. Following the completion of the acquisition, the chief financial officer owned 70,785 shares in the company, valued at approximately $1,061,775. This trade represents a 2.91% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Robert Joseph Ball acquired 2,200 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The shares were bought at an average price of $15.18 per share, with a total value of $33,396.00. Following the acquisition, the chief executive officer directly owned 278,866 shares in the company, valued at $4,233,185.88. This represents a 0.80% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders bought 5,200 shares of company stock worth $78,236. Company insiders own 29.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Federated Hermes Inc. bought a new position in shares of Shoulder Innovations during the 3rd quarter worth $2,510,000. TimesSquare Capital Management LLC purchased a new stake in Shoulder Innovations in the third quarter worth about $4,799,000. Readystate Asset Management LP bought a new position in Shoulder Innovations during the 3rd quarter worth about $511,000. Monashee Investment Management LLC purchased a new position in Shoulder Innovations during the 3rd quarter valued at about $502,000. Finally, Board of Trustees of The Leland Stanford Junior University purchased a new position in Shoulder Innovations during the 3rd quarter valued at about $170,000.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on SI. Piper Sandler reaffirmed an “overweight” rating and set a $19.00 price target (up from $18.00) on shares of Shoulder Innovations in a research note on Friday, May 8th. BTIG Research increased their price objective on shares of Shoulder Innovations from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $21.00.

About Shoulder Innovations

Shoulder Innovations (NYSE:SI) is a medical device company focused on the design, development and commercialization of shoulder implant systems and related surgical instruments for orthopedic surgery. The company’s product portfolio includes modular shoulder prostheses, humeral and glenoid components, and instrumentation kits designed to facilitate both primary and revision shoulder arthroplasty procedures. Emphasizing a patient-centric approach, Shoulder Innovations works to offer implant solutions that aim to restore mobility and reduce post-operative complications.

In addition to its core implant offerings, Shoulder Innovations provides comprehensive clinical support and training programs for surgeons and operating room teams.